Who are Renacidin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vitamin B4, SODIUM PICOSULFATE, Osmoprep, Diuretic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gluconolactone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Renacidin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Renacidin (GLUCONOLACTONE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calculi Dissolution Agent [EPC]. Area: Urology.

marketed Calculi Dissolution Agent [EPC] Glucosylceramidase Urology Small molecule Live · refreshed every 30 min

Target snapshot

Renacidin (GLUCONOLACTONE) — United Guardian.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Renacidin TARGET	GLUCONOLACTONE	United Guardian	marketed	Calculi Dissolution Agent [EPC]	Glucosylceramidase	1990-01-01
Vitamin B4	ADENINE		marketed	Calculi Dissolution Agent [EPC]	Phosphatidylinositol 4-kinase, PI4K, Leucine-rich repeat serine/threonine-protein kinase 2, Xanthine dehydrogenase/oxidase	2021-01-01
SODIUM PICOSULFATE	SODIUM PICOSULFATE		marketed	Calculi Dissolution Agent [EPC]		2012-01-01
Osmoprep	sodium phosphate, monobasic, monohydrate	Salix Pharms	marketed	Calculi Dissolution Agent [EPC]		2000-01-01
Diuretic	Diuretic	Reprieve Cardiovascular, Inc	marketed	Calculi Dissolution Agent [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-06-22 — Osmoprep · 7687075 · US

Sponsor landscape (Calculi Dissolution Agent [EPC] class)

· 2 drugs in this class
Reprieve Cardiovascular, Inc · 1 drug in this class
Salix Pharms · 1 drug in this class
United Guardian · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Renacidin — Competitive Intelligence Brief. https://druglandscape.com/ci/gluconolactone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing